US2012245116A1PendingUtilityA1

Inhibiting GS-FDH to Modulate No Bioactivity

57
Assignee: STAMLER JONATHAN SPriority: Jan 11, 2001Filed: Jun 8, 2012Published: Sep 27, 2012
Est. expiryJan 11, 2021(expired)· nominal 20-yr term from priority
Inventors:Jonathan S. StamlerLimin LiuAlfred HausladenRaphael Nudelman
A61P 9/00A61P 9/10A61P 7/00A61P 9/12A61P 31/04A61P 31/10A61P 33/10A61P 35/00A61P 29/00A61K 38/063A61P 11/00A61K 31/365A61P 15/10A61K 31/7056A61P 11/06A61P 19/02A61P 13/08A61P 1/16
57
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Patients needing NO donor therapy or inhibition of pathologically proliferating cells or increased NO bioactivity are treated with a therapeutically effective amount of an inhibitor of glutathione-dependent formaldehyde dehydrogenase.

Claims

exact text as granted — not AI-modified
1 . A method for treating a patient afflicted with cystic fibrosis comprising administering to said patient a therapeutically effective amount of at least one inhibitor of glutathione-dependent formaldehyde dehydrogenase. 
     
     
         2 . The method of  claim 1 , wherein the inhibitor is a competitor for NAD +  binding. 
     
     
         3 . The method of  claim 2 , wherein the competitor for NAD +  binding is NAD+ or a derivative thereof. 
     
     
         4 . The method of  claim 1 , wherein the inhibitor is a ribonucleoside analog. 
     
     
         5 . The method of  claim 1 , wherein the inhibitor is D-glutathione. 
     
     
         6 . The method of  claim 1 , wherein the inhibitor is mycophenolic acid. 
     
     
         7 . The method of  claim 1 , wherein the inhibitor is ribavirin.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.